Doxepin (Sinequan)
Doxepin
Pfizer Laboratories (Pty) Ltd
Registration
- Applicant
- Pfizer Laboratories (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Sinequan CAPSULE DOXEPIN HYDROCHLORIDE 11,53 MG | Not listed | B0131B/1.2/131 | Registered | Not determined | None |
| Sinequan* EACGH CAPSULE CONTAINS DOXEPIN 50 mg | Not listed | E0004E/2.6.5/4 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S5: Doxepin
- except when intended for application to the skin.
Consolidated Schedules 06 July 2026, line 9395
S4: Doxepin
- when intended for application to the skin.
Consolidated Schedules 06 July 2026, line 6114
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
3-(6H-Benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
Drag to rotate. Structure from PubChem CID 3158.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.